Call for Abstracts
Abstract Submission Period
|October 18 (Mon), 2021 –|
|We deeply appreciate for Submitting Abstracts.
Abstract Submission has closed.
Abstract Submission Guideline
|Abstract Title||Limited to 100 characters|
|Abstract Body||Without a Figure / Table
Limited to 2,000 characters
With a Figure / Table
|Total number of Authors||Up to 20 authors|
|Total number of Affiliations||Up to 10 affiliations|
The submitted abstract must describe unpublished work.
Please do not submit multiple copies of the same abstract.
Late abstract submission will not be accepted.
Abstracts can be accepted as Oral / Poster presentation.
Abstracts with Innovative Approach will be selected as the Excellent Oral Presentations.
- Poster Discussion
There will be discussions with moderators on excellent poster presentations.
- Mini Poster Presentation
You register your presentation slides in advance and present it.
There will be no presentations or Q&As.
Attendees can view the e-Poster.
There will be no poster viewing at the venue.
Please select a category for your presentation from Categories and submit your abstract.
The Program Committee will make the final decision on the presentation categories.
|A-03||Oncogenes/Tumor Suppressor Genes|
|A-06||Cell Cycle/DNA Damage and Repair|
|A-07||Transcriptional Regulation and Signal Transduction|
|A-09||Cancer Stem Cells|
|A-15||New Drugs/Drug Delivery System|
|A-16||Others (Basic Science)|
|Screening and Prevention||B-01||Screening Mammography|
|B-03||Improvement of Screening rate, Promotion activities|
|B-05||Screening by liquid|
|B-06||Secondary Examination (Detailed Examination)|
|B-08||Screening under the Circumstance of COVID-19|
|C-05||New Imaging modality|
|C-06||Others (Diagnostic Imaging)|
|Pathological Diagnosis||D-01||Benign Tumor|
|D-02||Borderline Lesions/Difficult to Distinguish Lesions|
|D-07||Non-epithelial or Unclassifiable Tumors|
|D-08||Assessment of Surgical Margin|
|D-09||Sentinel Lymph Node Diagnosis|
|D-11||Therapeutic Effect of Preoperative Systemic Therapy|
|D-12||Primary and Metastatic Lesions|
|D-16||Others (Pathological Diagnosis)|
|Intervention||E-01||Fine Needle Aspiration Cytology|
|Multi gene panel/Liquid biopsy||G-01||Gene Panel Testing|
|G-03||Others (Gene Panel / Liquid Biopsy)|
|Social Health Medicine||H-01||Medical Epidemiology, Social Epidemiology|
|H-02||Genetic Medical Research|
|H-04||Health Informatics, Preventive Medicine|
|Medical Communication||I-01||Medical Communication|
|I-03||Online Medical Care|
|Women's Health||J-01||Risk Factor, Prevention|
|J-03||Preservation of Fertility|
|Hereditary Breast Cancer||K-01||Genetic Testing|
|K-03||Biology, Clinico-Pathological Feature|
|K-04||Surveillance, Risk reduction surgery|
|K-05||Approach to the Family Member|
|K-06||Others (Treatment of Hereditary Breast Cancer)|
|Surgical Treatment||L-01||Sentinel Lymph Node Biopsy|
|L-02||Preoperative Systemic Therapy and Sentinel Lymph Node Biopsy|
|L-04||Surgical Treatment for Ipsilateral Breast Tumor Recurrence|
|L-05||Minimally Invasive Surgical Treatment|
|L-07||Breast-conserving Surgery and Cosmesis|
|L-08||Surgical Treatment for Locoregional Recurrence|
|L-09||Surgical Treatment for Distant Metastatic Lesions|
|L-13||Others (Surgical Treatment)|
|Oncoplastic Surgery / Breast Reconstruction||M-01||Oncoplastic Surgery|
|Radiation Therapy||N-01||Radiation Therapy after Breast Conserving Therapy|
|N-02||Postmastectomy Radiation Therapy|
|N-03||Adverse Events due to Radiation Therapy|
|N-04||New Radiation Therapy Technology, Method, Equipment|
|N-05||Radiation Therapy for Metastasis/Recurrence|
|N-06||Radiation Therapy Nursing|
|N-07||Others (Radiation Therapy)|
|Systemic Therapy (Preoperative, Postoperative)||O-01||Preoperative Hormone Therapy|
|O-03||Preoperative Molecular Targeted Therapy|
|O-04||Postoperative Hormone Therapy|
|O-06||Postoperative Molecular Targeted Therapy|
|O-07||Immune Checkpoint inhibitors|
|O-08||Hormone Receptor Positive|
|O-12||Others (Systemic Therapy, Pre- and Postoperative)|
|Systemic Therapy (Metastasis, Recurrence)||P-01||Hormone Therapy|
|P-03||Molecular Targeted Therapy|
|P-04||Immune Checkpoint Inhibitors|
|P-05||Hormone Receptor Positive|
|P-09||Others (Systemic Therapy, Metastasis and Recurrence)|
|Clinical Trials||Q-01||Clinical Trials (Systemic Therapy)|
|Q-02||Clinical Trials (except Systemic Therapy)|
|Q-03||Clinical Trials Currently in Progress|
|Medication Management, Guidance, Safety Management||R-01||Medication Management, Guidance|
|R-03||Others (Medication Management, Guidance, Safety Management )|
|Team Medicine/Medical Cooperation||S-01||Satisfaction of Patients, Families, and Medical staff|
|S-04||The Role of Pharmacists|
|S-05||The Role of Nurses|
|S-08||Others (Team Medicine/Medical Cooperation)|
|Medical Treatment for Specific Patients and Pathophysiology||T-01||Juvenile Breast Cancer|
|T-02||Elderly Breast Cancer|
|T-03||Male Breast Cancer|
|T-04||Bilateral Breast Cancer|
|T-05||Special Histopathological Type|
|T-06||Inflammatory Breast Cancer|
|T-07||Locally Advanced Breast Cancer|
|T-08||Occult Breast Cancer|
|T-09||Treatment of Breast Cancer Patients with Comorbidity|
|T-10||Others (Medical Treatment for Specific Patients and Pathophysiology)|
|Palliative Medicine||U-01||Symptom Relief|
|U-03||Social support, QOL Improvement|
|U-04||Others (Palliative Medicine)|
|Psychological and Social Support||W-01||Psycho-oncology|
|W-02||Advanced Care Planning|
|W-03||Patient Support Activities, Patient Groups, Family Support|
|W-04||Others (Psychological and Social Support)|
|Big Data||X-01||Image Information, Pathological Information|
|X-02||Others (Big Data)|
|Artificial Intelligence||Y-01||Omics Data|
|Y-02||Clinical Application (Diagnosis)|
|Y-03||Others (Artificial Intelligence)|
|Breast Cancer Treatment Under COVID-19||Z-01||Breast Cancer Treatment Triage|
|Z-02||Breast Cancer Treatment for COVID-19 Patients|
|Z-03||Preventing Infection, Patient Support|
|Z-04||Others (Breast Cancer Treatment Under COVID-19)|
|Lifestyle/Work Style/Education||AA-01||A New Way of Living and Working with COVID-19|
|AA-02||Work Style Reform, Task Shift|
|AA-03||Education, Human Resources Development|
|AA-04||Others (Lifestyle/Work Style/Education)|
|Case Report||AB-01||Diagnosis (Pathology, Images, etc.)|
|AB-08||Others (Case Report)|
Your presentation data will be released on our website for around 3 months after the Meeting.
Please select if you agree with it.
In case your abstract is accepted as the e-Poster and do not agree with it, your abstract will be withdrawn.
In case your abstract is selected as other than the e-Poster and you do not agree with it, your abstract might be withdrawn depending on session.
Conflict of Interest Disclosure
The author is required to report applicable COI (Conflict of Interest) in the past three years by completing the “Conflict of Interest Disclosure” part in the Abstract Submission process. Please check the details here.
We will send a notification by email around April in 2022.
The 30th JBCS will be held as a Hybrid Meeting (Onsite & Online).
We will inform you of more details later.
The 30th JBCS organizing committee encourages breast care specialists in other countries and regions to submit abstracts for oral / poster presentations.
After confirming the guidelines below, please submit your abstract.
All submitted abstracts are eligible for the travel grant application.
- Breast care specialists who apply from countries and regions other than Japan are eligible.
- An applicant must be the first author and presenter of the submitted abstract.
- Travel grant will be provided for the awardees after their presentations onsite.
- Please note that complimentary accommodation will not be offered, and all arrangements for the applicant’s transportation to the venue and accommodation during the congress period will be the applicant’s responsibility.
- Result of the review will be announced in acceptance notifications sent by e-mail in the end of April, 2022.
- There is no age limitation.